News
BIAF
3.920
-1.51%
-0.060
bioAffinity Reports Surge in CyPath Lung Test Sales
TipRanks · 2d ago
BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1
TipRanks · 2d ago
bioAffinity Technologies Reports Q1 CyPath Lung Diagnostic Unit Sales Up 146% YoY
Benzinga · 2d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 2d ago
bioAffinity CyPath Lung unit sales jump 146% in Q1 2026
Reuters · 2d ago
Weekly Report: what happened at BIAF last week (0323-0327)?
Weekly Report · 4d ago
bioAffinity Technologies Posts New Investor Presentation Materials
TipRanks · 03/26 12:42
bioAffinity Launches Virtual Roundtables on CyPath Lung Adoption
TipRanks · 03/25 21:15
What's Going On With bioAffinity Technologies Stock Wednesday?
Benzinga · 03/25 14:51
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 03/25 12:05
bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion
Reuters · 03/25 12:02
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 03/24 17:05
3 Penny Stocks to Watch Now, 3/24/26
TipRanks · 03/24 14:13
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 03/23 17:05
Weekly Report: what happened at BIAF last week (0316-0320)?
Weekly Report · 03/23 09:57
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/20 12:05
What's Going On With bioAffinity Stock Thursday?
Benzinga · 03/19 13:13
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 03/18 12:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 03/17 21:12
bioAffinity Showcases CyPath Lung Case Study in Diagnostics
TipRanks · 03/17 21:08
More
Webull provides a variety of real-time BIAF stock news. You can receive the latest news about bioAffinity Tech through multiple platforms. This information may help you make smarter investment decisions.
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.